Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients

• Published in: Journal of clinical immunology 2018-05, Vol.38 (4), p.503-512
• Main Authors: Bienvenu, Boris, Cozon, Grégoire, Mataix, Yves, Lachaud, Dominique, Alix, Antoine, Hoarau, Cyrille, Antier, Daniel, Hachulla, Eric, Brice, Sylvie, Viallard, Jean-François, Tamisier, Stéphanie, Fauchais, Anne-Laure, Renon-Carron, Françoise, Clerson, Pierre, Fardini, Yann, Crave, Jean-Charles, Miossec, Pierre
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Contrarian investing; Hedging; Immunodeficiency; Immunoglobulin G; Immunoglobulins; Immunology; Infectious Diseases; Internal Medicine; Life Sciences; Medical Microbiology; Original; Original Article; Patients; Primary immunodeficiencies; Quality of life; Self-administration; Short sales
• ISSN: 0271-9142; 1573-2592
• DOI: 10.1007/s10875-018-0507-x

Purpose Subcutaneous immunoglobulin replacement therapy (IgRT) may be administered once a week with a pump or every other day with a syringe (rapid push). The objective of the study was to compare the impact of pump and rapid push infusions on patient’s life quality index (LQI). Methods This study was a randomized, crossover, multicenter, non-inferiority trial conducted in adults with primary immunodeficiency (PID) accustomed to weekly infusions at home by pump. Patients used pump or rapid push for 3 months each according to the randomized sequence. Main criterion was PID-LQI factor I (treatment interference). Non-inferiority ratio was set at 90%. Results Thirty patients entered the study; 28 completed the two periods. IgRT exposure was similar during each period. At the end of each period, mean LQI factor 1 was 87.0 (IC95% [80.3; 94.3]) and 77.80 (IC95% [71.5; 84.7]) for pump and rapid push, respectively. There was a slightly larger effect of rapid push on treatment interference than with pump so that the primary endpoint could not be met. No difference was found on other LQI components, satisfaction (TSQM), or quality of life (SF36v2). Eight patients declared to prefer rapid push while 19 others preferred pump. Of rapid push infusions, 67.2% led to local reactions vs 71.8% of pump infusions ( p  = 0.11) illustrating its good tolerance. Rapid push and pump infusions achieved similar trough IgG levels with similar incidence of infections. Rapid push saved 70% of administration cost when compared to pump. Conclusions Since IgRT is a lifelong treatment in PID patients, individualization of treatment is of paramount importance. Rapid push is a new administration method in the physician’s armamentarium which is preferred by some patients and is cost-effective. ClinicalTrials.gov Identifier NCT02180763 Clinical Implications Self-administration of small volumes of immunoglobulins at home, every other day, using a syringe (rapid push) is a cost-effective alternative to administration of larger volumes by pump once a week. Capsule Summary This study compared subcutaneous infusions of immunoglobulins either weekly via a pump or every other day via a syringe (rapid push). Rapid push is preferred by some patients and is cost-effective, therefore completing a physician’s armamentarium.